Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Raily Aesthetic Medicine International Holdings Limited (2135.HK)
Hangzhou, CN
Raily Aesthetic Medicine International Holdings Limited is an investment holding company primarily engaged in providing a comprehensive range of cosmetic medical services. Its operations are structured into three principal segments: Aesthetic Medical Services, Consulting Services, and the distribution of Aesthetic Medical Equipment Products. The company's service offerings include various aesthetic procedures such as: Surgical interventions: encompassing cosmetic surgeries performed on different areas of the face or body. Minimally invasive treatments: largely consisting of aesthetic injection procedures. Aesthetic dermatology: featuring diverse energy-based treatments. Aesthetic dental care: including orthodontic services, dental implants, and teeth whitening. Management consulting: providing specialized advisory services for aesthetic medical practices. Furthermore, Raily trades in medical equipment and sells surgical implants alongside aesthetic medical skincare products. The company manages and operates a network of four private, for-profit aesthetic medical clinics located in China's Zhejiang and Anhui Provinces. It serves a diverse clientele, including individual retail customers and other aesthetic medical institutions. Founded in 2008 and headquartered in Hangzhou, People's Republic of China, Raily Aesthetic Medicine International Holdings Limited operates as a subsidiary of Ruide Consultation Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.60% | -6.82% | -12.77% | -16.89% | -9.56% | -18.00% | +11.82% | -80.62% | -96.85% | -93.49% | -93.49% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Care Facilities: +10.2%-7.4% Q4'25: +12.3% (vs Q4'23)
-
EPS growth Medical - Care Facilities: +19.2%+100.5% ★ Q4'25: +123.1% (vs Q4'23)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+15.3% Q4'25: +26.9% (vs Q4'23)
-
EBIT margin Medical - Care Facilities: +11.3%+2.7% Q4'25: +12.1% (vs Q4'23)
-
ROIC Medical - Care Facilities: +6.8%+3.0% Q4'25: +43.9% (vs Q4'23)
-
Share dilution Medical - Care Facilities: +0.0%+479.6% Q4'25: +33.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×2.19× ★ Q4'25: 0.64× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-28 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | B- | 3/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 3/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Haishu Fu | Founder & Executive Chairman of the Board | 989.2K | male |
| Jianliang Song | CEO, Executive Director & Group President | 693.4K | male |
| Ying Wang | Executive Director & GM of business development department | 605.5K | male |
| Chunxiu Zhang | Group Chief Financial Officer | 509.6K | female |
| Oi Fat Chan | Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2135.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
